These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 11970747)

  • 1. Exemestane in breast cancer: current status and future directions.
    Lønning PE
    Clin Breast Cancer; 2000 Sep; 1 Suppl 1():S28-33. PubMed ID: 11970747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of aromatase inactivators in the treatment of breast cancer.
    Lønning PE
    Int J Clin Oncol; 2002 Aug; 7(4):265-70. PubMed ID: 12202980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology and clinical experience with exemestane.
    Lønning PE
    Expert Opin Investig Drugs; 2000 Aug; 9(8):1897-905. PubMed ID: 11060785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exemestane: a novel aromatase inactivator for breast cancer.
    Jones SA; Jones SE
    Clin Breast Cancer; 2000 Oct; 1(3):211-6. PubMed ID: 11899645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exemestane: a review of its use in postmenopausal women with breast cancer.
    Deeks ED; Scott LJ
    Drugs; 2009; 69(7):889-918. PubMed ID: 19441873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exemestane: a review of its use in postmenopausal women with advanced breast cancer.
    Clemett D; Lamb HM
    Drugs; 2000 Jun; 59(6):1279-96. PubMed ID: 10882163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status and future potential role of exemestane in the treatment of early and advanced breast cancer (Review).
    Crucitta E; Fornier MN; Locopo N; Silvestris N; Lorusso V; De Lena M
    Int J Oncol; 2002 Jun; 20(6):1283-8. PubMed ID: 12012011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
    Mouridsen HT; Robert NJ
    MedGenMed; 2005 Aug; 7(3):20. PubMed ID: 16369246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aromatase inhibitors in the breast cancer clinic: focus on exemestane.
    Van Asten K; Neven P; Lintermans A; Wildiers H; Paridaens R
    Endocr Relat Cancer; 2014 Feb; 21(1):R31-49. PubMed ID: 24434719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exemestane for breast cancer prevention: a feasible strategy?
    Lønning PE
    Clin Cancer Res; 2005 Jan; 11(2 Pt 2):918s-24s. PubMed ID: 15701887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exemestane as adjuvant treatment of early breast cancer: intergroup exemestane study/tamoxifen exemestane adjuvant multicenter trials.
    Jones SE
    Clin Breast Cancer; 2006 Feb; 6 Suppl 2():S41-4. PubMed ID: 16595025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience with exemestane in the treatment of early and advanced breast cancer.
    Lønning PE; Geisler J
    Expert Opin Drug Metab Toxicol; 2008 Jul; 4(7):987-97. PubMed ID: 18624685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug safety evaluation of exemestane.
    Lintermans A; Neven P; Paridaens R
    Expert Opin Drug Saf; 2011 May; 10(3):473-87. PubMed ID: 21428848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. To switch or not to switch: should the updated Intergroup Exemestane Study alter our decision?
    Iddon J; Bundred NJ
    Expert Rev Anticancer Ther; 2008 Jan; 8(1):9-13. PubMed ID: 18095878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study.
    Markopoulos C; Polychronis A; Zobolas V; Xepapadakis G; Papadiamantis J; Koukouras D; Lappas H; Gogas H
    Breast Cancer Res Treat; 2005 Sep; 93(1):61-6. PubMed ID: 16184460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exemestane: new preparation. No tangible advance in metastatic breast cancer after tamoxifen failure.
    Prescrire Int; 2001 Aug; 10(54):108-9. PubMed ID: 11718178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of exemestane in the management of breast cancer.
    Wong NS; Pritchard KI
    Expert Opin Pharmacother; 2005 Oct; 6(13):2353-63. PubMed ID: 16218894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exemestane in postmenopausal women with early or advanced breast cancer: a review.
    Bertelli G; Gangadhara S
    Expert Opin Pharmacother; 2010 Aug; 11(11):1933-42. PubMed ID: 20569090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.